Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Fenaux P, et al. Among authors: arrizabalaga b. N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892. N Engl J Med. 2020. PMID: 31914241 Free article. Clinical Trial.
Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
Villegas A, Arrizabalaga B, Fernández-Lago C, Castro M, Mayans JR, González-Porras JR, Duarte RF, Remacha AF, Luño E, Gasquet JA. Villegas A, et al. Among authors: arrizabalaga b. Curr Med Res Opin. 2011 May;27(5):951-60. doi: 10.1185/03007995.2011.561834. Epub 2011 Mar 7. Curr Med Res Opin. 2011. PMID: 21381892 Clinical Trial.
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Sánchez-García J, Del Cañizo C, Lorenzo I, Nomdedeu B, Luño E, de Paz R, Xicoy B, Valcárcel D, Brunet S, Marco-Betes V, García-Pintos M, Osorio S, Tormo M, Bailén A, Cerveró C, Ramos F, Diez-Campelo M, Such E, Arrizabalaga B, Azaceta G, Bargay J, Arilla MJ, Falantes J, Serrano-López J, Sanz GF; Spanish Group on Myelodysplastic Syndromes (GES MD). Sánchez-García J, et al. Among authors: arrizabalaga b. Br J Haematol. 2014 Jul;166(2):189-201. doi: 10.1111/bjh.12876. Epub 2014 Apr 10. Br J Haematol. 2014. PMID: 24716538 Free article.
Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients.
Sánchez JMH, Lumbreras E, Díez-Campelo M, González T, López DA, Abáigar M, Del Rey M, Martín AÁ, de Paz R, Erquiaga S, Arrizabalaga B, Hernández-Rivas JM, Vicente AER. Sánchez JMH, et al. Among authors: arrizabalaga b. Pharmacogenomics J. 2020 Oct;20(5):664-671. doi: 10.1038/s41397-020-0154-5. Epub 2020 Feb 4. Pharmacogenomics J. 2020. PMID: 32015457
Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.
Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Ardanaz MT, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L. Calvo X, et al. Among authors: arrizabalaga b. Mod Pathol. 2016 Dec;29(12):1541-1551. doi: 10.1038/modpathol.2016.146. Epub 2016 Aug 26. Mod Pathol. 2016. PMID: 27562492 Free article.
Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Blanco ML, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu M, Ferrer A, Sanz GF, Florensa L. Calvo X, et al. Among authors: arrizabalaga b. Am J Hematol. 2017 Jul;92(7):614-621. doi: 10.1002/ajh.24732. Epub 2017 May 9. Am J Hematol. 2017. PMID: 28370234 Free article.
Oxidative imbalance in low/intermediate-1-risk myelodysplastic syndrome patients: The influence of iron overload.
Ivars D, Orero MT, Javier K, Díaz-Vico L, García-Giménez JL, Mena S, Tormos C, Egea M, Pérez PL, Arrizabalaga B, Ruiz MÁ, Yagüe N, Tormo M, Sancho-Tello R, Gomes A, Algueró C, O'Connor JE, Sáez GT, Carbonell F, Collado R. Ivars D, et al. Among authors: arrizabalaga b. Clin Biochem. 2017 Nov;50(16-17):911-917. doi: 10.1016/j.clinbiochem.2017.05.018. Epub 2017 May 29. Clin Biochem. 2017. PMID: 28571970
45 results